Latest Commercial Execution News

ClearVue Technologies has appointed Professor Rebecca Yang, a leading authority in building-integrated photovoltaics and sustainable building technologies, to its board, boosting its technical leadership as it pursues global commercialisation of advanced solar glass solutions.

BluGlass has landed a A$1.4 million Phase II deal with Uviquity, extending their collaboration on cutting-edge photonic integrated circuits and visible GaN lasers.

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.

Dataworks Group has arranged a $1.5 million unsecured working capital facility with a three-month term and 18% interest, aiming to strengthen liquidity and support ongoing and new commercial contracts without diluting equity.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

ClearVue Technologies has secured A$6 million through a $5 million institutional placement and a fully underwritten $1 million Share Purchase Plan, aiming to bolster its balance sheet and fund international expansion and product development.

Hydralyte USA secures A$392,000 through a share placement, appoints two new non-executive directors, and implements significant cost reductions following CEO resignation as it targets cash-flow break-even and strategic expansion.

Simble Solutions edges closer to $1 million in annual recurring revenue as major customer rollouts advance and its NanoSensor program moves forward along a structured development pathway.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

A US court has dismissed Identitii's patent infringement claim against JPMorgan Chase, citing patent ineligibility. Identitii plans to appeal, while its core business remains unaffected.

Cadoux Ltd has cleared a critical technical and commercial hurdle by qualifying its premiumHPA® high purity alumina for use in the EU-backed SAFELOOP electric vehicle battery project, opening doors to potential offtake deals and boosting its standing in the critical minerals market.